Literature DB >> 26619353

Interactions of conjugate vaccines and co-administered vaccines.

H Findlow1, R Borrow1,2.   

Abstract

Conjugate vaccines play an important role in the prevention of infectious diseases such as those caused by the bacteria Haemophilus influenzae (Hi) type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae. Vaccines developed against these 3 pathogens utilize 3 main carrier proteins, non-toxic mutant of diphtheria toxin (CRM197), diphtheria toxoid (DT) and tetanus toxoid (TT). Current pediatric immunisation schedules include the administration of several vaccines simultaneously, therefore increasing the potential for immune interference (both positively and negatively) to the antigens administered. Knowledge of vaccine interactions is principally derived from clinical trials, these are reviewed here to explore immune interference which may result of from carrier-specific T-cell helper interactions, bystander interference and carrier induced epitopic suppression.

Entities:  

Keywords:  Vaccines; conjugate; immunisation; infectious disease; interactions; pediatric

Mesh:

Substances:

Year:  2016        PMID: 26619353      PMCID: PMC4962715          DOI: 10.1080/21645515.2015.1091908

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  13 in total

Review 1.  Glycoconjugate vaccines and immune interference: A review.

Authors:  Ron Dagan; Jan Poolman; Claire-Anne Siegrist
Journal:  Vaccine       Date:  2010-06-25       Impact factor: 3.641

Review 2.  Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

Authors:  Markus Knuf; Leszek Szenborn; Masnuel Moro; Christian Petit; Nancy Bermal; Laurence Bernard; Ilse Dieussaert; Lode Schuerman
Journal:  Pediatr Infect Dis J       Date:  2009-04       Impact factor: 2.129

Review 3.  Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.

Authors:  R A Insel
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

4.  Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.

Authors:  Emmanuel Grimprel; Jacek Wysocki; Florence Boisnard; Stéphane Thomas; Grace Mwawasi; Donna Reynolds
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

5.  Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.

Authors:  Elizabeth Miller; Nick Andrews; Pauline Waight; Helen Findlow; Lindsey Ashton; Anna England; Elaine Stanford; Mary Matheson; Joanna Southern; Elizabeth Sheasby; David Goldblatt; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2010-12-29

6.  Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age.

Authors:  N R E Kitchin; J Southern; R Morris; F Hemme; S Thomas; M W Watson; K Cartwright; E Miller
Journal:  Arch Dis Child       Date:  2006-05-02       Impact factor: 3.791

7.  Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.

Authors:  Shamez N Ladhani; Nick J Andrews; Pauline Waight; Bassam Hallis; Mary Matheson; Anna England; Helen Findlow; Xilian Bai; Ray Borrow; Polly Burbidge; Emma Pearce; David Goldblatt; Elizabeth Miller
Journal:  Vaccine       Date:  2014-12-12       Impact factor: 3.641

8.  Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom.

Authors:  Jo Southern; Ray Borrow; Nick Andrews; Rhonwen Morris; Pauline Waight; Michael Hudson; Paul Balmer; Helen Findlow; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

9.  Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age.

Authors:  S J Moss; A C Fenton; J Toomey; A Grainger; R Borrow; P Balmer; J Smith; A R Gennery
Journal:  Clin Vaccine Immunol       Date:  2009-12-30

10.  Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.

Authors:  Moya Burrage; Andrew Robinson; Ray Borrow; Nick Andrews; Joanna Southern; Jamie Findlow; Sarah Martin; Carol Thornton; David Goldblatt; Michael Corbel; Dorothea Sesardic; Keith Cartwight; Peter Richmond; Elizabeth Miller
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  10 in total

1.  Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.

Authors:  Tsung-Che Chang; Yoshiyuki Manabe; Keita Ito; Ryuku Yamamoto; Kazuya Kabayama; Shino Ohshima; Yoshie Kametani; Yukari Fujimoto; Chun-Cheng Lin; Koichi Fukase
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

2.  Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.

Authors:  Marc Lipsitch; Lucy M Li; Scott Patterson; James Trammel; Christine Juergens; William C Gruber; Daniel A Scott; Ron Dagan
Journal:  Vaccine       Date:  2017-12-14       Impact factor: 3.641

3.  A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.

Authors:  Sarah Joseph; Killian Quinn; Aldona Greenwood; Alethea V Cope; Paul F McKay; Peter J Hayes; Jakub T Kopycinski; Jill Gilmour; Aleisha N Miller; Christof Geldmacher; Yuka Nadai; Mohamed I M Ahmed; David C Montefiori; Len Dally; George Bouliotis; David J M Lewis; Roger Tatoud; Ralf Wagner; Mariano Esteban; Robin J Shattock; Sheena McCormack; Jonathan Weber
Journal:  Front Immunol       Date:  2017-02-22       Impact factor: 7.561

4.  Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines.

Authors:  Paolo Bonanni; Sara Boccalini; Angela Bechini; Ornella Varone; Giulio Matteo; Federica Sandri; Giovanni Gabutti
Journal:  Hum Vaccin Immunother       Date:  2019-12-10       Impact factor: 3.452

5.  PglB function and glycosylation efficiency is temperature dependent when the pgl locus is integrated in the Escherichia coli chromosome.

Authors:  Vanessa S Terra; Marta Mauri; Thippeswamy H Sannasiddappa; Alexander A Smith; Mark P Stevens; Andrew J Grant; Brendan W Wren; Jon Cuccui
Journal:  Microb Cell Fact       Date:  2022-01-05       Impact factor: 5.328

6.  Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Authors:  Sonu Shrestha; Lisa K Stockdale; Madhav C Gautam; Meeru Gurung; Shuo Feng; Pratistha Maskey; Simon Kerridge; Sarah Kelly; Merryn Voysey; Bhishma Pokhrel; Piyush Rajbhandari; Stephen Thorson; Bibek Khadka; Ganesh Shah; Karin S Scherer; Dominic Kelly; David R Murdoch; Shrijana Shrestha; Andrew J Pollard
Journal:  J Infect Dis       Date:  2021-09-01       Impact factor: 5.226

7.  Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation.

Authors:  Olivia Bonduelle; Chloé Chaudesaigues; Monica Tolazzi; Ehsan Suleiman; Simon de Bernard; Karine Alves; Julien Nourikyan; Mylene Bohec; Laura G Baudrin; Dietmar Katinger; Patrice Debré; Gabriella Scarlatti; Vincent Vieillard; Behazine Combadière
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

8.  Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen.

Authors:  Neeraj Kapoor; Satoshi Uchiyama; Lucy Pill; Leslie Bautista; Angie Sedra; Lu Yin; Maritoni Regan; Ellen Chu; Taylor Rabara; Melissa Wong; Peter Davey; Jeff Fairman; Victor Nizet
Journal:  ACS Omega       Date:  2022-07-11

Review 9.  Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.

Authors:  Ger T Rijkers; Laura Ie Yousif; Simone Mc Spoorenberg; Frans J van Overveld
Journal:  Risk Manag Healthc Policy       Date:  2018-03-27

10.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.